Jennerex, Transgene Form JV To Develop Cancer Compound
This article was originally published in PharmAsia News
Executive Summary
Jennerex and Transgene have joined hands by signing an agreement for the development and commercialization of an anti-cancer compound, which has been tentatively named JX-594